DE69233104D1 - Herstellung von Antikörpern - Google Patents

Herstellung von Antikörpern

Info

Publication number
DE69233104D1
DE69233104D1 DE69233104T DE69233104T DE69233104D1 DE 69233104 D1 DE69233104 D1 DE 69233104D1 DE 69233104 T DE69233104 T DE 69233104T DE 69233104 T DE69233104 T DE 69233104T DE 69233104 D1 DE69233104 D1 DE 69233104D1
Authority
DE
Germany
Prior art keywords
antibodies
antibody production
same
recombinant
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69233104T
Other languages
English (en)
Other versions
DE69233104T2 (de
Inventor
James Scott Crowe
Alan Peter Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233104(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919115284A external-priority patent/GB9115284D0/en
Priority claimed from GB919116594A external-priority patent/GB9116594D0/en
Priority claimed from GB929206284A external-priority patent/GB9206284D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69233104D1 publication Critical patent/DE69233104D1/de
Publication of DE69233104T2 publication Critical patent/DE69233104T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
DE69233104T 1991-07-15 1992-07-14 Herstellung von Antikörpern Revoked DE69233104T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9115284 1991-07-15
GB919115284A GB9115284D0 (en) 1991-07-15 1991-07-15 Production of antibodies
GB919116594A GB9116594D0 (en) 1991-08-01 1991-08-01 Production of antibodies
GB9116594 1991-08-01
GB929206284A GB9206284D0 (en) 1992-03-23 1992-03-23 Production of antibodies
GB9206284 1992-03-23

Publications (2)

Publication Number Publication Date
DE69233104D1 true DE69233104D1 (de) 2003-07-31
DE69233104T2 DE69233104T2 (de) 2004-05-13

Family

ID=27265765

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233104T Revoked DE69233104T2 (de) 1991-07-15 1992-07-14 Herstellung von Antikörpern

Country Status (16)

Country Link
US (1) US5876961A (de)
EP (1) EP0523949B1 (de)
JP (1) JP3502093B2 (de)
KR (1) KR100255717B1 (de)
AT (1) ATE243747T1 (de)
AU (1) AU662752B2 (de)
CA (1) CA2111858A1 (de)
DE (1) DE69233104T2 (de)
ES (1) ES2199216T3 (de)
FI (1) FI940144A (de)
HU (1) HU220355B (de)
IE (1) IE922287A1 (de)
IL (1) IL102490A0 (de)
NZ (1) NZ243558A (de)
TW (1) TW373023B (de)
WO (1) WO1993002190A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
ATE414720T1 (de) 2000-12-05 2008-12-15 Alexion Pharma Inc Rationell entworfene antikörper
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
US11674240B2 (en) 2004-07-06 2023-06-13 Pfizer Inc. Universal antibody libraries
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
CN103555652A (zh) 2006-09-13 2014-02-05 Abbvie公司 细胞培养改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008094316A2 (en) 2006-09-22 2008-08-07 Stowers Institute Of Medical Research Novel branchiostoma derived fluorescent proteins
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
US8278106B2 (en) 2008-11-14 2012-10-02 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US10288611B2 (en) 2009-11-23 2019-05-14 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
SG10201913376XA (en) 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP6205175B2 (ja) * 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015095195A1 (en) 2013-12-16 2015-06-25 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
CN106459212B (zh) 2014-02-28 2021-07-13 美勒斯公司 结合erbb-2和erbb-3的抗体
RS57928B1 (sr) 2015-07-10 2019-01-31 Merus Nv Antitela koja vezuju humani cd3
NZ742290A (en) 2015-10-23 2019-11-29 Merus Nv Binding molecules that inhibit cancer growth
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
MA49846A (fr) 2017-08-09 2020-06-17 Merus Nv Anticorps qui se lient à l'egfr et à cmet
TW201930351A (zh) 2017-10-06 2019-08-01 日商小野藥品工業股份有限公司 雙特異性抗體
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
US20220281977A1 (en) 2019-07-30 2022-09-08 Ono Pharmaceutical Co., Ltd. Bispecific antibody
EP4011918A4 (de) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. Dual-spezifisches protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296024A (en) * 1974-12-09 1981-10-20 Merck & Co., Inc. Human immune serum globulin with high hepatitis A antibody titer
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
EP0131878A3 (de) * 1983-07-19 1987-08-05 Sloan-Kettering Institute For Cancer Research Verfahren zur Herstellung menschlicher monoklonaler Antikörper
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1989000607A1 (en) * 1987-07-09 1989-01-26 The United States Of America, As Represented By Th Preparation of human monoclonal antibodies of selected specificity and isotypes
NZ226694A (en) * 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
AU4429989A (en) * 1988-10-19 1990-05-14 Dow Chemical Company, The A novel family of high affinity, modified antibodies for cancer treatment
DE3921211C1 (de) * 1989-06-28 1990-11-29 Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch
JPH05500608A (ja) * 1989-09-19 1993-02-12 セントカー・インコーポレーテツド ヒトモノクローナル抗体の産生を改良する方法
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
EP0440147B2 (de) * 1990-02-01 2014-05-14 Siemens Healthcare Diagnostics Products GmbH Herstellung und Verwendung von Genbanken menschlicher Antikörper ("Human-Antikörper-Bibliotheken")
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.

Also Published As

Publication number Publication date
FI940144A0 (fi) 1994-01-12
AU662752B2 (en) 1995-09-14
NZ243558A (en) 1994-06-27
ATE243747T1 (de) 2003-07-15
KR100255717B1 (ko) 2000-05-01
HUT69798A (en) 1995-09-28
WO1993002190A1 (en) 1993-02-04
JPH07502882A (ja) 1995-03-30
FI940144A (fi) 1994-01-12
EP0523949B1 (de) 2003-06-25
HU220355B (hu) 2001-12-28
US5876961A (en) 1999-03-02
EP0523949A1 (de) 1993-01-20
IL102490A0 (en) 1993-01-14
JP3502093B2 (ja) 2004-03-02
DE69233104T2 (de) 2004-05-13
AU2279892A (en) 1993-02-23
TW373023B (en) 1999-11-01
HU9400110D0 (en) 1994-05-30
ES2199216T3 (es) 2004-02-16
IE922287A1 (en) 1993-01-27
CA2111858A1 (en) 1993-02-04

Similar Documents

Publication Publication Date Title
DE69233104D1 (de) Herstellung von Antikörpern
DK0433225T3 (da) Fremgangsmåde til fremstilling af biologisk aktivt protein, f.eks. TGF
DK0791571T3 (da) Benzoylderivater
DK140996A (da) Fremgangsmåde til fremstilling af 2,3,4,5-tetraflour-6-alkyl-benzoesyreforbindelser
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
ATE207080T1 (de) Multivalente antigen-bindende proteine
DE60114865D1 (de) Heterologe herstellung von polyketiden
DE68918217T2 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
FI943724A0 (fi) Stabiloidut radiofarmaseuttiset pakkaukset
FI903464A0 (fi) Foerfarande foer oxiderande denaturering av proteinanalyter.
ATE6032T1 (de) Biologisch aktive substanzen, deren herstellung aus menschlichem kasein und zubereitungen, die sie enthalten.
DE59308628D1 (de) Verfahren zur Herstellung von Faktor VIII
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
ATE103779T1 (de) Brausekomponente und verfahren zu ihrer herstellung.
NL7017514A (en) Purification of proteins
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DE69527868T2 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE3877015D1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
NO961353L (no) Resulfurisert austenittisk rustfritt stål med forbedret bearbeidbarhet
DE3481814D1 (de) Kosmetikum.
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
ES2056844T3 (es) Antigeno de treponema hyodysenteriae y sus usos.
ATE1239T1 (de) Verfahren zur herstellung von 4-amino-5-chlor-1-phenyl-pyridazon-(6).
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
IT8421612A0 (it) Vettore clonante, procedimento per la sua costruzione e procedimentodi concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation